{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T04:00:25Z","timestamp":1776916825640,"version":"3.51.2"},"reference-count":61,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T00:00:00Z","timestamp":1748563200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002975","name":"Sumitomo Pharma Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002975","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Genetics and Metabolism"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.ymgme.2025.109151","type":"journal-article","created":{"date-parts":[[2025,5,26]],"date-time":"2025-05-26T12:05:01Z","timestamp":1748261101000},"page":"109151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Enzyme replacement therapy using a modified \u03b1-N-acetylgalactosaminidase to suppress progressive glycolipid accumulation and escape from antidrug antibody formation in young human NAGA-transgenic\/Gla-knockout mice"],"prefix":"10.1016","volume":"145","author":[{"given":"Hitoshi","family":"Sakuraba","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takahiro","family":"Tsukimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Shiga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Saito","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youichi","family":"Tajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikuo","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomoko","family":"Fukushige","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tadayasu","family":"Togawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymgme.2025.109151_bb0005","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2025.109151_bb0010","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1073\/pnas.97.1.365","article-title":"Infusion of alpha-galactosidase A reduces tissue globotriaosylceramide storage in patients with Fabry disease","volume":"97","author":"Schiffmann","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2025.109151_bb0015","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJM200107053450102","article-title":"Safety and efficacy of recombinant human alpha-galactosidase A replacement therapy in Fabry\u2019s disease","volume":"345","author":"Eng","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ymgme.2025.109151_bb0020","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ymgme.2020.04.003","article-title":"Pharmacokinetics and pharmacodynamics of JR-051, a biosimilar of agalsidase beta, in healthy adults and patients with Fabry disease: phase I and II\/III clinical studies","volume":"130","author":"Nakamura","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109151_bb0025","doi-asserted-by":"crossref","first-page":"1395287","DOI":"10.3389\/fgene.2024.1395287","article-title":"Pegunigalsidase alfa: a novel, pegylated recombinant alpha-galactosidase enzyme for the treatment of Fabry disease","volume":"15","author":"Germain","year":"2024","journal-title":"Front. Genet."},{"key":"10.1016\/j.ymgme.2025.109151_bb0030","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1097\/GIM.0b013e3181f13b75","article-title":"Effects of enzyme replacement therapy in Fabry disease-a comprehensive review of the medical literature","volume":"12","author":"Lidove","year":"2010","journal-title":"Genet. Med."},{"key":"10.1016\/j.ymgme.2025.109151_bb0035","doi-asserted-by":"crossref","first-page":"3705","DOI":"10.2147\/DDDT.S207856","article-title":"Cardio-renal outcomes with long-term agalsidase alfa enzyme replacement therapy: a 10-year Fabry outcome survey (FOS) analysis","volume":"13","author":"Ramaswami","year":"2019","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ymgme.2025.109151_bb0040","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1093\/ckj\/sfaa065","article-title":"Agalsidase beta treatment slows estimated glomerular filtration rate loss in classic Fabry disease patients: results from an individual patient data meta-analysis","volume":"14","author":"Ortiz","year":"2021","journal-title":"Clin. Kidney J."},{"key":"10.1016\/j.ymgme.2025.109151_bb0045","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.ymgme.2018.11.008","article-title":"Antibodies against recombinant alpha-galactosidase A in Fabry disease: subclass analysis and impact on response to treatment","volume":"126","author":"van der Veen","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109151_bb0050","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1186\/s13023-018-0877-4","article-title":"Deep characterization of the anti-drug antibodies developed in Fabry disease patients, a prospective analysis from the French multicenter cohort FFABRY","volume":"13","author":"Mauhin","year":"2018","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/j.ymgme.2025.109151_bb0055","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1111\/j.1365-2125.2009.03501.x","article-title":"Enzyme therapy in Fabry disease: severe adverse events associated with anti-agalsidase cross-reactive IgG antibodies","volume":"68","author":"Tesmoingt","year":"2009","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/j.ymgme.2025.109151_bb0060","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0047805","article-title":"Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome","volume":"7","author":"Rombach","year":"2012","journal-title":"PloS One"},{"key":"10.1016\/j.ymgme.2025.109151_bb0065","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1007\/s10545-011-9400-y","article-title":"Fabry disease, enzyme replacement therapy and the significance of antibody responses","volume":"35","author":"Deegan","year":"2012","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/j.ymgme.2025.109151_bb0070","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","article-title":"Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta","volume":"66","author":"Linthorst","year":"2004","journal-title":"Kidney Int."},{"key":"10.1016\/j.ymgme.2025.109151_bb0075","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1681\/ASN.2014121226","article-title":"Serum-mediated inhibition of enzyme replacement therapy in Fabry disease","volume":"27","author":"Lenders","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.ymgme.2025.109151_bb0080","article-title":"Anti-drug antibody formation in Japanese Fabry patients following enzyme replacement therapy","volume":"25","author":"Tsukimura","year":"2020","journal-title":"Mol Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2025.109151_bb0085","series-title":"The Metabolic and Molecular Basis of Inherited Disease","first-page":"3483","article-title":"\u03b1-N-acetylgalactosaminidase deficiency: Schindler disease","author":"Desnick","year":"2001"},{"key":"10.1016\/j.ymgme.2025.109151_bb0090","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.ajhg.2009.09.016","article-title":"Use of a modified alpha-N-acetylgalactosaminidase in the development of enzyme replacement therapy for Fabry disease","volume":"85","author":"Tajima","year":"2009","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2025.109151_bb0095","doi-asserted-by":"crossref","first-page":"21560","DOI":"10.1074\/jbc.M110.118588","article-title":"Interconversion of the specificities of human lysosomal enzymes associated with Fabry and Schindler diseases","volume":"285","author":"Tomasic","year":"2010","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2025.109151_bb0100","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.3389\/fpls.2017.01026","article-title":"Human alpha galactosidases transiently produced in Nicotiana benthamiana leaves: new insights in substrate specificities with relevance for Fabry disease","volume":"8","author":"Kytidou","year":"2017","journal-title":"Front. Plant Sci."},{"key":"10.1016\/j.ymgme.2025.109151_bb0105","doi-asserted-by":"crossref","first-page":"10042","DOI":"10.1074\/jbc.RA118.001774","article-title":"Nicotiana benthamiana \u03b1-galactosidase A1.1 can functionally complement human \u03b1-galactosidase A deficiency associated with Fabry disease","volume":"293","author":"Kytidou","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ymgme.2025.109151_bb0110","doi-asserted-by":"crossref","first-page":"2812","DOI":"10.1073\/pnas.0712309105","article-title":"Elevated globotriaosylsphingosine is a hallmark of Fabry disease","volume":"105","author":"Aerts","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2025.109151_bb0115","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jchromb.2011.11.020","article-title":"Quantification of the Fabry marker lysoGb3 in human plasma by tandem mass spectrometry","volume":"883-884","author":"Kr\u00fcger","year":"2012","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"10.1016\/j.ymgme.2025.109151_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0127048","article-title":"Nano-LC-MS\/MS for quantification of lyso-Gb3 and its analogues reveals a useful biomarker for Fabry disease","volume":"10","author":"Sueoka","year":"2015","journal-title":"PloS One"},{"key":"10.1016\/j.ymgme.2025.109151_bb0125","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1007\/s10157-017-1525-3","article-title":"Plasma lyso-Gb3: a biomarker for monitoring Fabry patients during enzyme replacement therapy","volume":"22","author":"Sakuraba","year":"2018","journal-title":"Clin. Exp. Nephrol."},{"key":"10.1016\/j.ymgme.2025.109151_bb0130","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ymgme.2017.05.001","article-title":"Favourable effect of early versus late start of enzyme replacement therapy on plasma globotriaosylsphingosine levels in men with classical Fabry disease","volume":"121","author":"Arends","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109151_bb0135","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2021.12.004","article-title":"Early start of enzyme replacement therapy in pediatric male patients with classical Fabry disease is associated with attenuated disease progression","volume":"135","author":"van der Veen","year":"2022","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109151_bb0140","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00467-023-06050-5","article-title":"Impact of kidney biopsy on deciding when to initiate enzyme replacement therapy in children with Fabry disease","volume":"39","author":"Avarappattu","year":"2024","journal-title":"Pediatr. Nephrol."},{"key":"10.1016\/j.ymgme.2025.109151_bb0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ymgme.2022.106967","article-title":"Clinical outcomes among young patients with Fabry disease who initiated agalsidase beta treatment before 30 years of age: an analysis from the Fabry registry","volume":"138","author":"Hopkin","year":"2023","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109151_bb0150","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ymgme.2018.04.007","article-title":"The effect of enzyme replacement therapy on clinical outcomes in paediatric patients with Fabry disease \u2013 a systematic literature review by a European panel of experts","volume":"126","author":"Spada","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109151_bb0155","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1007\/s10038-005-0342-9","article-title":"Comparison of the effects of agalsidase alfa and agalsidase beta on cultured human Fabry fibroblasts and Fabry mice","volume":"51","author":"Sakuraba","year":"2006","journal-title":"J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2025.109151_bb0160","doi-asserted-by":"crossref","first-page":"2540","DOI":"10.1073\/pnas.94.6.2540","article-title":"\u03b1-Galactosidase a deficient mice: a model of Fabry disease","volume":"94","author":"Ohshima","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2025.109151_bb0165","doi-asserted-by":"crossref","first-page":"6423","DOI":"10.1073\/pnas.96.11.6423","article-title":"Aging accentuates and bone marrow transplantation ameliorates metabolic defects in Fabry disease mice","volume":"96","author":"Ohshima","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ymgme.2025.109151_bb0170","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/j.jmb.2004.01.035","article-title":"The molecular defect leading to Fabry disease: structure of human alpha-galactosidase","volume":"337","author":"Garman","year":"2004","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ymgme.2025.109151_bb0175","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S1096-7192(02)00151-8","article-title":"Structural basis of Fabry disease","volume":"77","author":"Garman","year":"2002","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109151_bb0180","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1006\/jmbi.1998.2401","article-title":"Asparagine and glutamine: using hydrogen atom contacts in the choice of side-chain amide orientation","volume":"285","author":"Word","year":"1999","journal-title":"J. Mol. Biol."},{"key":"10.1016\/j.ymgme.2025.109151_bb0185","doi-asserted-by":"crossref","first-page":"W368","DOI":"10.1093\/nar\/gki464","article-title":"H++: a server for estimating pKas and adding missing hydrogens to macromolecules","volume":"33","author":"Gordon","year":"2005","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.ymgme.2025.109151_bb0190","series-title":"AMBER 2020","author":"Case","year":"2020"},{"key":"10.1016\/j.ymgme.2025.109151_bb0195","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1063\/1.445869","article-title":"Comparison of simple potential functions for simulating liquid water","volume":"79","author":"Jorgensen","year":"1983","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.ymgme.2025.109151_bb0200","doi-asserted-by":"crossref","first-page":"3696","DOI":"10.1021\/acs.jctc.5b00255","article-title":"ff14SB: improving the accuracy of protein side chain and backbone parameters from ff99SB","volume":"11","author":"Maier","year":"2015","journal-title":"J. Chem. Theory Comput."},{"key":"10.1016\/j.ymgme.2025.109151_bb0205","doi-asserted-by":"crossref","DOI":"10.1063\/1.3073889","article-title":"Isothermal-isobaric molecular dynamics using stochastic velocity rescaling","volume":"130","author":"Bussi","year":"2009","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.ymgme.2025.109151_bb0210","doi-asserted-by":"crossref","first-page":"1196","DOI":"10.1103\/PhysRevLett.45.1196","article-title":"Crystal structure and pair potentials: a molecular-dynamics study","volume":"45","author":"Parrinello","year":"1980","journal-title":"Phys. Rev. Lett."},{"key":"10.1016\/j.ymgme.2025.109151_bb0215","doi-asserted-by":"crossref","first-page":"10089","DOI":"10.1063\/1.464397","article-title":"Particle mesh Ewald: an N \u00b7log(N) method for Ewald sums in large systems","volume":"98","author":"Darden","year":"1993","journal-title":"J. Chem. Phys."},{"key":"10.1016\/j.ymgme.2025.109151_bb0220","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","article-title":"GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers","volume":"1-2","author":"Abraham","year":"2015","journal-title":"SoftwareX"},{"key":"10.1016\/j.ymgme.2025.109151_bb0225","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1186\/1756-0500-5-367","article-title":"ACPYPE-antechamber python parser interface","volume":"5","author":"Sousa da Silva","year":"2012","journal-title":"BMC. Res. Notes"},{"key":"10.1016\/j.ymgme.2025.109151_bb0230","article-title":"Does administration of hydroxychloroquine\/amiodarone accelerate accumulation of globotriaosylceramide and globotriaosylsphingosine in Fabry mice?","volume":"28","author":"Tsukimura","year":"2021","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2025.109151_bb0235","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1086\/316953","article-title":"Fabry disease: preclinical studies demonstrate the effectiveness of alpha\u2013galactosidase A replacement in enzyme-deficient mice","volume":"68","author":"Ioannou","year":"2001","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/j.ymgme.2025.109151_bb0240","article-title":"Comparative study on incorporation of three recombinant human alpha-galactosidase a drugs (agalsidases) into cultured fibroblasts and organs\/tissues of Fabry mice","volume":"40","author":"Tsukimura","year":"2024","journal-title":"Mol. Genet. Metab. Rep."},{"key":"10.1016\/j.ymgme.2025.109151_bb0245","series-title":"The Metabolic and Molecular Basis of Inherited Disease","first-page":"3733","article-title":"\u03b1-Galactosidase A deficiency: Fabry disease","author":"Desnick","year":"2001"},{"key":"10.1016\/j.ymgme.2025.109151_bb0250","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/cbdd.14038","article-title":"Application of molecular dynamics simulation in biomedicine","volume":"99","author":"Wu","year":"2022","journal-title":"Chem. Biol. Drug Des."},{"key":"10.1016\/j.ymgme.2025.109151_bb0255","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.3390\/molecules27072105","article-title":"Molecular dynamics simulations: advances and applications","volume":"27","author":"Filipe","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ymgme.2025.109151_bb0260","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1006\/abbi.1994.1144","article-title":"Generation of one set of murine monoclonal antibodies specific for globo-series glycolipids: evidence for differential distribution of the glycolipids in rat small intestine","volume":"310","author":"Kotani","year":"1994","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ymgme.2025.109151_bb0265","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2022.104641","article-title":"Oral tolerance to prevent anti-drug antibody formation in protein replacement therapies","volume":"382","author":"Rana","year":"2022","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.ymgme.2025.109151_bb0270","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1111\/j.1365-2249.2004.02567.x","article-title":"Methotrexate reduces antibody responses to recombinant human alpha-galactosidase a therapy in a mouse model of Fabry disease","volume":"137","author":"Garman","year":"2004","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.ymgme.2025.109151_bb0275","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.clim.2017.01.014","article-title":"Anti-BlyS antibody reduces the immune reaction against enzyme and enhances the efficacy of enzyme replacement therapy in Fabry disease model mice","volume":"178","author":"Sato","year":"2017","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.ymgme.2025.109151_bb0280","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/joim.12647","article-title":"Impact of immunosuppressive therapy on therapy-neutralizing antibodies in transplanted patients with Fabry disease","volume":"282","author":"Lenders","year":"2017","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.ymgme.2025.109151_bb0285","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ymthe.2003.11.015","article-title":"AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice","volume":"9","author":"Ziegler","year":"2004","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymgme.2025.109151_bb0290","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ymgme.2020.08.005","article-title":"Detailed epitope mapping of neutralizing antidrug antibodies against recombinant \u03b1-galactosidase A in patients with Fabry disease","volume":"131","author":"Scharnetzki","year":"2020","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/j.ymgme.2025.109151_bb0295","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/cmdc.201800094","article-title":"Antibody epitope of human \u03b1-galactosidase A revealed by affinity mass spectrometry: a basis for reversing immunoreactivity in enzyme replacement therapy of Fabry disease","volume":"13","author":"Kukacka","year":"2018","journal-title":"ChemMedChem"},{"key":"10.1016\/j.ymgme.2025.109151_bb0300","doi-asserted-by":"crossref","first-page":"958","DOI":"10.3389\/fimmu.2018.00958","article-title":"Potential of murine IgG1 and human IgG4 to inhibit the classical complement and Fc\u03b3 receptor activation pathways","volume":"9","author":"Lilienthal","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymgme.2025.109151_bb0305","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0279389","article-title":"Increased number of T cells and exacerbated inflammatory pathophysiology in a human IgG4 knock-in MRL\/lpr mouse model","volume":"18","author":"Gon","year":"2023","journal-title":"PloS One"}],"container-title":["Molecular Genetics and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719225001428?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1096719225001428?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T07:55:28Z","timestamp":1764834928000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1096719225001428"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":61,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S1096719225001428"],"URL":"https:\/\/doi.org\/10.1016\/j.ymgme.2025.109151","relation":{},"ISSN":["1096-7192"],"issn-type":[{"value":"1096-7192","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Enzyme replacement therapy using a modified \u03b1-N-acetylgalactosaminidase to suppress progressive glycolipid accumulation and escape from antidrug antibody formation in young human NAGA-transgenic\/Gla-knockout mice","name":"articletitle","label":"Article Title"},{"value":"Molecular Genetics and Metabolism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymgme.2025.109151","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"109151"}}